Samenvatting
Leukaemia in neonates (infants <1 month) is rare, whereby neonatal acute myeloid leukaemia (AML) is more frequent than neonatal acute lymphoblastic leukaemia (ALL). High mortality rates are observed, though AML has a better prognosis than ALL. Neonatal leukaemia is typically presented with hepatosplenomegaly, leukaemia cutis and/or hyperleucocytosis. Congenital infections should be ruled out before diagnosis. Rearrangement of the . MLL gene is the most frequently occurring genetic aberration. Treatment includes intensive multi-agent chemotherapy, usually with age-related dose adjustments next to supportive care. Treatment intensification for ALL could be indicated in the future as the dismal prognosis is subject to high relapse rates in ALL.
| Originele taal-2 | Engels |
|---|---|
| Pagina's (van-tot) | 192-195 |
| Aantal pagina's | 4 |
| Tijdschrift | Seminars in Fetal and Neonatal Medicine |
| Volume | 17 |
| Nummer van het tijdschrift | 4 |
| DOI's | |
| Status | Gepubliceerd - aug 2012 |
| Extern gepubliceerd | Ja |
Vingerafdruk
Duik in de onderzoeksthema's van 'Diagnosis and management of neonatal leukaemia'. Samen vormen ze een unieke vingerafdruk.Citeer dit
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver